Network


Latest external collaboration on country level. Dive into details by clicking on the dots.

Hotspot


Dive into the research topics where Christopher Norbert GlaxoSmithKline Johnson is active.

Publication


Featured researches published by Christopher Norbert GlaxoSmithKline Johnson.


Archive | 2002

N-aroyl cyclic amine derivatives as orexin receptor antagonists

Clive Leslie Branch; Wai Ngor GlaxoSmithKline Chan; Amanda GlaxoSmithKline Johns; Christopher Norbert GlaxoSmithKline Johnson; David John Nash; Riccardo Novelli; Jean-Pierre Pilleux; Roderick Alan Porter; Rachel Elizabeth Anne Stead; Geoffrey GlaxoSmithKline Stemp


Archive | 2001

Morpholine derivatives as antagonists of orexin receptors

Clive Leslie Branch; Christopher Norbert GlaxoSmithKline Johnson; Alexander Baxter Smith; Geoffrey GlaxoSmithKline Stemp; Kevin GlaxoSmithKline Pharmaceutical Thewlis


Archive | 2002

Piperazine bis-amide derivatives and their use as antagonists of the orexin receptor

Clive Leslie Branch; Christopher Norbert GlaxoSmithKline Johnson; David John Nash; Geoffrey GlaxoSmithKline Stemp


Archive | 2002

3-arylsulfonyl-7-piperazinyl- indoles, -benzofurans and -benzothiophenes with 5-ht6 receptor affinity for treating cns disorders

Steven Mark GlaxoSmithKline SpA Bromidge; Christopher Norbert GlaxoSmithKline Johnson; Gregor James GlaxoSmithKline Macdonald; Mervyn GlaxoSmithKline Thompson; David R. Witty


Archive | 2002

7-sulfonyl-3-benzazepine derivatives as modulators of the dopamine receptor and their use for the treatment of cns disorders

Mahmood Ahmed; Steven Mark GlaxoSmithKline SpA Bromidge; Ian Thomson GlaxoSmithKline Forbes; Andrew Derrick GlaxoSmithKline Gribble; Christopher Norbert GlaxoSmithKline Johnson; Francis David GlaxoSmithKline King; Andrew P. Lightfoot; Gregor James GlaxoSmithKline Macdonald; Stephen Frederick Moss; Mervyn GlaxoSmithKline Thompson; David R. Witty


Archive | 2004

QUINOLINE COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM

Christopher Norbert GlaxoSmithKline Johnson; David R. Witty


Archive | 2003

Quinoline and aza-indole derivatives and their use as 5-ht6 ligands

Christopher Norbert GlaxoSmithKline Johnson; Gregor James GlaxoSmithKline Macdonald; Darren Jason Mitchell; Stephen Frederick Moss; Mervyn GlaxoSmithKline Thompson; David R. GlaxoSmithKline Witty


Archive | 2003

Benzenesulfonamide derivatives as antipsychotic agents

Steven Mark Bromidge; David Gwyn Cooper; Ian Thomson GlaxoSmithKline Forbes; Andrew Derrick GlaxoSmithKline Gribble; Christopher Norbert GlaxoSmithKline Johnson; Andrew P. Lightfoot; Stephen Frederick Moss; Andrew H. Payne; Shahzad Sharooq GlaxoSmithKline Rahman; David R. Witty


Archive | 2005

Radiolabelled quinoline-based ligands for the 5-ht6 receptor functionality

Antony David GlaxoSmithKline Gee; Laurent c; o GlaxoSmithKline Martarello; Christopher Norbert GlaxoSmithKline Johnson; David R. Witty


Archive | 2005

3-Arylsulfonyl-Quinolines as 5-Ht6 Receptor Antagonists for the Treatment of Cns Disorders

Christopher Norbert GlaxoSmithKline Johnson; Geoffrey GlaxoSmithKline Stemp; Mervyn GlaxoSmithKline Thompson; David Richard Witty

Collaboration


Dive into the Christopher Norbert GlaxoSmithKline Johnson's collaboration.

Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar

David Jones

University of California

View shared research outputs
Researchain Logo
Decentralizing Knowledge